Redefining R&D

How Immunoscience is Driving the Pipeline of the Future

Our Latest Stories

Ziyu Li inspects samples on a lab machine, wearing a white labcoat, purple gloves, and safety glasses.

Our Science

November 13, 2024

How Immunoscience is Transforming Treatment for Type 1 Diabetes

/assets/dotcom/content-app/events/banner-investors-events_20230703194346.jpg

Third quarter 2024 results

Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session.

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

Igniting the Potential in Everyone

We’re proud to be premium partner of Paris 2024.

Science and sport aren’t that different. Just like athletes do, we overcome setbacks to keep moving forward, not just for ourselves, but for our patients, colleagues, families and friends.

About Us

Who We Are

We are an innovative global healthcare company.

Our Pipeline

5

Therapeutic areas

78

Compounds in clinical development

27

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases

November 14, 2024
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
November 6, 2024
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
October 25, 2024
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
October 24, 2024
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI